HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antitumor effect of large doses IL-2-activated HLA haploidentical peripheral blood stem cells on refractory metastatic solid tumor treatment.

AbstractOBJECTIVE:
The traditional immunotherapy for patients with refractory metastatic solid tumors is limited because tumors induce immunosuppression. New treatment is, therefore, needed. The aim of this study was to evaluate the clinical efficacy of infusion of high-dose interleukin (IL)-2-activated allogeneic haploidentical peripheral blood stem cells (haplo-PBSCTs) on patients with an advanced stage of refractory solid tumors.
METHODS:
This study involved 11 patients with refractory metastatic tumors and haploidentical relatives as donors for haplo-PBSCs. The therapeutic outcome of the IL-2-activated haplo-PBSC infusion and patients' cytokine levels were evaluated. The cytotoxicity of IL-2-activated haplo-PBSCs for tumor cells was determined using in vitro cytotoxicity assays.
RESULTS:
A range from 2.5 to 5.6 x 10(10) of activated haplo-PBSCs were harvested after exposure to rhIL-2, along with a significant increase in the proportion of natural killer (NK) cells and activated lymphocytes (CD69+ and CD25+), and enhanced cytotoxicity of haplo-PBSCs for several tumor cell lines. Following treatment, 1 (1/11) patient achieved a partial response (PR), 1 (1/11) achieved a mild response (MR), 6 (6/11) achieved stable disease (SD), and 3 (3/11) achieved progressive disease (PD). For all of the 11 patients, the median progression-free survival (PFS) was 5 months (3-14 months). We also observed the phenomenon of Th2 shifted to Th1, which played a crucial role in cancer immunotherapy.
CONCLUSIONS:
The adoptive transfusion of IL-2-activated haplo-PBSCs has potent antitumor effects both in vitro and in vivo. This finding suggests that IL-2-activated haplo-PBSCs may serve as an alternative therapy for advanced-stage solid tumors, especially for those patients who are refractory or ineligible for chemo- or radiotherapy.
AuthorsXiu-Bao Ren, Jin-Pu Yu, Shui Cao, Bao-Zhu Ren, Hui Li, Hong Liu, Wei-Ping Min, Xi-Shan Hao
JournalCancer biotherapy & radiopharmaceuticals (Cancer Biother Radiopharm) Vol. 22 Issue 2 Pg. 223-34 (Apr 2007) ISSN: 1084-9785 [Print] United States
PMID17600469 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • HLA Antigens
  • Interleukin-2
Topics
  • Adult
  • Aged
  • Blood Donors
  • Cell Differentiation
  • Female
  • HLA Antigens (genetics, immunology)
  • Haplotypes (genetics)
  • Hematopoietic Stem Cells (drug effects, immunology)
  • Humans
  • Immunotherapy
  • Interleukin-2 (pharmacology)
  • Male
  • Middle Aged
  • Neoplasm Metastasis (pathology)
  • Neoplasms (pathology, therapy)
  • Phenotype
  • Th1 Cells (cytology)
  • Th2 Cells (cytology)
  • Tomography, X-Ray Computed
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: